Advanced prostate cancer treatment milestone
The 13th of September 2018 marks a momentous occasion for UCMI at our Wesley clinic in Auchenflower. Unitingcare Medical Imaging completed the first Queensland Lutetium 177 PSMA Therapy for advanced prostate cancer on 10 August 2017. This week marks the 100th treatment administered to hopeful men in their quest to fight the disease.
This is an exciting milestone for UCMI and furthermore the availability to offer these services to the Queensland community as a whole. Lutetium-177 PSMA is a new type of theranostics treatment for advanced prostate cancer. The treatment works by delivering an injection of therapeutic radiation directly to the prostate cancer and its metastases.
This non-invasive prostate cancer treatment aims to reduce the size of the tumour/s and stop them from multiplying and as a result easing the symptoms caused by the tumours. Furthermore in the majority of cases, Lutetium 177 PSMA therapy stabilises or improves disease that has previously been progressive.
Professor David Wong leads a dedicated team treating men with Lutetium-177 PSMA treatment for advanced prostate cancer. Lutetium-177 PSMA is part of the broader portfolio of Theranostics treatments. Similarly, Unitingcare Medical Imaging now offers Theranostic treatments for other disease processes.